EpiTan answers ASX trading query
Monday, 18 August, 2003
Melbourne-based EpiTan's share price (ASX:EPT) has doubled since April, but that's just because of increased market awareness, the company has told the Australian Stock Exchange.
Answering to a 'please explain' from the ASX about the company's rocketing price, EpiTan company secretary Iain Kirkwood said market awareness of clinical trials of its primary drug candidate, Melanotan, a tanning drug, was responsible.
The Phase IIb trials are due to be wound up in September, and EpiTan is scheduled to meet with US Food and Drug Administration officials in October to discuss US-based human implant trials of the drug.
Kirkwood said EpiTan was seeking to partner a larger drug firm to commercialise Melanotan. At press time, the company's share price was AUD$0.90, up from $0.82 when the market opened this morning.
Common arthritis drug also lowers blood pressure
Scientists have known for a while that methotrexate helps with inflammation, but it may also help...
AI enables precise gene editing
A newly developed tool utilises AI to predict how cells repair their DNA after it is cut by gene...
Shingles vaccine may reduce risk of heart attack and stroke
Vaccination with either the recombinant herpes zoster vaccine or the live-attenuated zoster...
